Novartis Financial Results – Q2 2026
Novartis announces the company’s financial results for the second quarter and first half of 2026.
Latest news
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
30 years of Novartis, powered by 250 years of innovation
Rooted in a legacy of scientific discovery, Novartis continues to advance breakthrough medicines that redefine the future of care for patients.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.